1
|
Li Y, Zhang J, Falo L, Larregina A, Sumpter T. 365 The MrgprB2/X2 is regulated by the neurokinin 2 receptor in mast cells in the skin. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Baxendell H, Haduch A, Alwine J, Naumov N, Falo L, Sumpter T. 1034 Lipoxin A4 diminishes mast cell activation and allergic contact hypersensitivity. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.1046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
3
|
Wang Z, Divito S, Shufesky W, Sumpter T, Wang H, Tkacheva OA, Wang W, Liu C, Larregina AT, Morelli AE. Dendritic cell therapies in transplantation revisited: deletion of recipient DCs deters the effect of therapeutic DCs. Am J Transplant 2012; 12:1398-408. [PMID: 22500950 PMCID: PMC3365643 DOI: 10.1111/j.1600-6143.2012.04060.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
A critical goal in transplantation is the achievement of donor-specific tolerance, minimizing the use of immunosuppressants. Dendritic cells (DCs) are antigen (Ag) presenting cells (APCs) with capability to promote immunity or tolerance. The immune-regulatory properties of DCs have been exploited for generation of tolerogenic/immunosuppressive (IS) DCs that, when transfer systemically, prolong allograft survival in murine models. Surprisingly, the in vivo mechanisms of therapies based on (donor- or recipient-derived) ISDCs in transplantation remain unknown, given that previous studies investigated their effects in vitro, or ex vivo after transplantation. Since once injected, ISDCs are short-lived and transfer Ag to recipient APCs, we assessed the role of recipient DCs by depleting them at the time of ISDC-therapy in a mouse model of cardiac transplantation. The results indicate that, contrary to the accepted paradigm, systemically administered ISDCs reduce the alloresponse and prolong allograft survival, not by themselves, but through conventional DCs (cDCs) of the recipient. These findings raise doubts on the advantages of the currently used ISDC-therapies, since the immune-regulatory properties of the injected ISDC do not seem to be functionally relevant in vivo, and the quiescent/pro-tolerogenic status of cDCs may be compromised in patients with end-stage diseases that require transplantation.
Collapse
Affiliation(s)
- Z. Wang
- T.E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213,Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213,The Heart Lung and Esophageal Surgery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| | - S.J. Divito
- T.E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213,Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| | - W.J. Shufesky
- T.E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213,Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| | - T. Sumpter
- Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| | - H. Wang
- The Heart Lung and Esophageal Surgery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| | - O. A. Tkacheva
- Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| | - W. Wang
- The Heart Lung and Esophageal Surgery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| | - C. Liu
- The Heart Lung and Esophageal Surgery Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| | - A. T. Larregina
- Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213,Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| | - A. E. Morelli
- T.E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213,Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15213,Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213
| |
Collapse
|
4
|
Cardinal J, Turnquist H, Sumpter T, Tsung A, Geller D, Thomson A. QS179. Overexpression of ST2L by Rapamycin Conditioned Dendritic Cells Facilitates Responsiveness to IL-33. J Surg Res 2009. [DOI: 10.1016/j.jss.2008.11.479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
5
|
Abstract
Derivatized bovine adenosine deaminase is used in enzyme replacement therapy and as an adjunct to gene therapy against severe combined immunodeficiency syndrome. Although a gene sequence is known for human adenosine deaminase, the structure of the bovine enzyme has not been characterized. Structure studies using mass spectrometry are reported here that evaluate sequence, processing, post-translational modifications and the extent of homology between the human protein and its therapeutic surrogate.
Collapse
Affiliation(s)
- M A Kelly
- Department of Chemistry and Biochemistry, University of Maryland Baltimore County 21228, USA
| | | | | | | | | | | |
Collapse
|